Eyal Rabinovich
Venture Capital Investor @ Octopus Ventures
London, United Kingdom
Eyal Rabinovich is a Series B investor at Octopus Ventures in London focused on Software and Information Technology. Eyal Rabinovich, an entrepreneur, software engineer and user-experience evangelist. Eyal particularly specializes in developing and delivering products and ideas.He has proven experience in developing consumer facing products while understanding and adapting to customer needs. In the past years Eyal has been commercially involved in a variety ofdifferent industries, and has strong experience in leading development from inception to a complete product. Eyal was previously employed as a Senior Software Engineer at Hegde-Tech Financial Engineering, Lipman Electronic Engineering Ltd. and as an officer at an elite unit of the IDF’s Navy.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Eyal Rabinovich invests in
Stages Eyal Rabinovich invests in
Countries Eyal Rabinovich invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 3 (38%)
- Information Technology 3 (38%)
- EdTech 2 (25%)
- Education 2 (25%)
- CRM 1 (13%)
Stage
- Series B 4 (50%)
- Series A 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
Country
- United States 3 (38%)
- Israel 2 (25%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Noogata
|
Noogata is the radically simple, no-code artificial intelligence (AI) data analytics for the enterprise. The company provides modular, expandable, single-platform, and analytics solutions. | $16M / Series A / Apr 12, 2022 | |
Walnut
|
Walnut offers a failure-free, codeless, and 100% customizable platform that empowers every sales rep to own their successful sales demo experience. It aims to redefine inside sales in the new age. The first-of-its-kind codeless platform integrates with a company's CRMs and data sources, making the process of creating sales demos both automatedand customizable. Walnut's drag-and-drop solution eliminates the need for back-end teams and streamlines the demoing process by placing full control back in the hands of the sales team. To achieve a fail-proof experience, the demos are run live, even when the real product is offline. Founded in 2020 by serial entrepreneurs Yoav VIlner and Danni Friedland, Walnut is headquartered in New York City. | $35M / Series B / Jan 18, 2022 | |
|
Walnut
|
Walnut offers a failure-free, codeless, and 100% customizable platform that empowers every sales rep to own their successful sales demo experience. It aims to redefine inside sales in the new age. The first-of-its-kind codeless platform integrates with a company's CRMs and data sources, making the process of creating sales demos both automatedand customizable. Walnut's drag-and-drop solution eliminates the need for back-end teams and streamlines the demoing process by placing full control back in the hands of the sales team. To achieve a fail-proof experience, the demos are run live, even when the real product is offline. Founded in 2020 by serial entrepreneurs Yoav VIlner and Danni Friedland, Walnut is headquartered in New York City. | $15M / Series A / Aug 31, 2021 | |
Medisafe
|
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications.By addressing the major challenges of medication management utilizing a datascience-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%.Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc. | $30M / Series C / Feb 25, 2021 | |
CB4
|
Once a week, stores with CB4 get a list of SKUs that they can sell much more of now. Each store’s unique selling patterns and operating conditions determine which products are on the list—so no two stores get the same set of recommendations. Sometimes products are underselling because of how or where they're placed. Sometimes there’s alabeling issue or inventory discrepancy. Sometimes they’re plain out of stock. We don’t slow you down with irrelevant, stale insights. We only highlight SKUs that will add significant revenue now. Stores make quick, easy fixes—like taking a product out of backstock or ordering more units—to gain new sales and satisfy shoppers. They also share what they found and how they fixed it. Spotlight’s algorithms use this to learn more about how each store operates and send more actionable, higher value recommendations over time. | $16M / Series B / Mar 27, 2019 | |
Jolt
|
Jolt builds a network of innovative learning spaces where professionals learn together from world-class instructors. Jolt members upskill themselves through short and effective learning sessions as part of their weekly routine, and are part of a global tribe of lifelong learners.Jolt's learning spaces provides short and effective learningsessions as part of their weekly routine, held in futuristically designed classrooms on small campuses. Jolt was founded in 2015 and is headquartered in Tel Aviv, Israel. | $7.2M / Seed / Oct 16, 2018 | |
Memrise
|
Memrise is a language learning platform available in iOS, android, and web. It has more than 150 language courses across 25 languages. The app has over 40 million registered users, all courses are totally free to learn, and there is no advertising. There are extra features and learn modes that can be unlocked with a Memrise Pro subscription.Memrise has been profitable since late 2016. | $15.5M / Series B / Jun 11, 2018 | |
|
Medisafe
|
Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications.By addressing the major challenges of medication management utilizing a datascience-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%.Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc. | $14.5M / Series B / Mar 01, 2017 |
Co-Investors
About Octopus Ventures
Octopus Ventures is a venture capital firm that offers support to companies at various stages of their journey, from idea conception to IPO. They allocate over £200 million annually to invest in sectors such as health, fintech, deep tech, consumer, and B2B software, with a focus on making a positive impact. Their experienced team assists portfoliocompanies in scaling rapidly. Octopus Ventures' investment philosophy extends beyond monetary support, involving time, energy, and focus to work closely with founders for success. Notable companies they have backed include ManyPets, Cazoo, Depop, Elvie, and WaveOptics. Their operations span London and New York, with a network of partners in the U.S. and Asia.
Octopus Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alliott Cole
CEO
|
|||
Jo Oliver
Director
|
|||
Luke Hakes
Partner
|
|||
Uthish Ranjan
Partner
|
|||
Zoe Chambers
Early Stage Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eyal Rabinovich invest in?
Eyal Rabinovich invests primarily in Software, Information Technology and EdTech startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eyal Rabinovich?
Public channels for Eyal Rabinovich include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eyal Rabinovich last invest?
The most recent investment recorded for Eyal Rabinovich closed in Apr 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
